MCID: RNL014
MIFTS: 80

Renal Cell Carcinoma

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Renal Cell Carcinoma

MalaCards integrated aliases for Renal Cell Carcinoma:

Name: Renal Cell Carcinoma 54 38 12 50 24 71 29 14 69
Adenocarcinoma of Kidney 12 50 24 71
Hereditary Clear Cell Renal Cell Carcinoma 56 69
Renal Carcinoma, Chromophobe, Somatic 54 13
Nonpapillary Renal Cell Carcinoma 12 14
Hypernephroma 12 71
Rcc 12 71
Hereditary Clear Cell Renal Cell Adenocarcinoma 56
Renal Cell Carcinoma, Clear Cell, Somatic 54
Conventional Renal Cell Carcinoma 69
Renal Cell Carcinoma Non-Papillary 71
Renal Cell Carcinoma, Nonpapillary 29
Conventional Renal Cell Carcinoma 71
Renal Cell Carcinoma, Somatic 54
Common Renal Cell Carcinoma 71
Clear Cell Renal Carcinoma 71
Renal Cell Adenocarcinoma 50
Carcinoma, Renal Cell 42
Carcinoma Renal Cell 52
Ccrcc 71
Crcc 71

Characteristics:

Orphanet epidemiological data:

56

HPO:

32
renal cell carcinoma:
Inheritance sporadic


Classifications:

Orphanet: 56  
Rare renal diseases


External Ids:

OMIM 54 144700
Disease Ontology 12 DOID:0050387 DOID:4450
MeSH 42 D002292
NCIt 47 C9385
Orphanet 56 ORPHA422526
ICD10 via Orphanet 34 C64
SNOMED-CT via HPO 65 41607009 702391001
UMLS 69 C0007134

Summaries for Renal Cell Carcinoma

OMIM : 54
The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700)

MalaCards based summary : Renal Cell Carcinoma, also known as adenocarcinoma of kidney, is related to renal cell carcinoma, papillary and collecting duct carcinoma, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma is VHL (Von Hippel-Lindau Tumor Suppressor), and among its related pathways/superpathways are Development HGF signaling pathway and Apoptosis Pathway. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and lung, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

Novus Biologicals : 53 Renal cell carcinoma originates in the proximal renal tube and is the most common form of kidney cancer. Renal cell carcinoma is resistant to radiation therapy and chemotherapy, however some cases respond to immunotherapy. Interleukin-2 has produced remission in some patients, as has functional restoration of the VHL gene.

UniProtKB/Swiss-Prot : 71 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 72 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
id Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, papillary 35.7 CA9 MET PRCC TFE3
2 collecting duct carcinoma 34.0 DIRC2 FHIT FLCN MET RNF139
3 mucinous tubular and spindle renal cell carcinoma 34.0 CA9 FHIT HNF1A OGG1 PBRM1 SETD2
4 chromophobe renal cell carcinoma 12.4
5 clear cell renal cell carcinoma 12.3
6 clear cell papillary renal cell carcinoma 12.3
7 sarcomatoid renal cell carcinoma 12.1
8 hereditary renal cell carcinoma 12.1
9 eosinophilic variant of chromophobe renal cell carcinoma 12.0
10 tubulocystic renal cell carcinoma 12.0
11 acquired cystic disease-associated renal cell carcinoma 12.0
12 chromophil renal cell carcinoma 12.0
13 renal cell carcinoma 4 12.0
14 hereditary conventional renal cell carcinoma 11.9
15 renal cell carcinoma associated with neuroblastoma 11.9
16 multilocular clear cell renal cell carcinoma 11.9
17 leiomyomatosis and renal cell cancer 11.8
18 classic variant of chromophobe renal cell carcinoma 11.8
19 renal clear cell carcinoma 11.6
20 von hippel-lindau syndrome 11.5
21 cleft lip palate dysmorphism kumar type 11.4 CA9 FLCN MET OGG1 PBRM1 RNF139
22 renal oncocytoma 11.2
23 coloboma of superior eyelid 11.2 TFE3 VEGFA VHL
24 primary malignant melanoma of the conjunctiva 11.2 AKT1 MET VEGFA
25 renal tubular transport disease 11.2 PBRM1 SETD2 VHL
26 central nervous system vasculitis 11.2 CA9 VEGFA VHL
27 metanephric adenoma 11.1
28 birt-hogg-dube syndrome 11.1
29 malignant growth hormone secreting neoplasm of pituitary 11.0 FLCN MET
30 melanoma, cutaneous malignant 8 11.0
31 multilocular cystic clear cell renal cell neoplasm of low malignant potential 11.0
32 gallbladder cancer 10.9 AKT1 MET VEGFA
33 dental caries 10.9 AKT1 HNF1B VEGFA
34 gastric cancer, somatic 10.9 FHIT MET VEGFA
35 nasal cavity disease 10.9 AKT1 HNF1B VEGFA
36 ovarian brenner tumor 10.9 AKT1 ATM CA9 FHIT FLCN IL2
37 brown-vialetto-van laere syndrome 10.8 AKT1 IL2 VEGFA
38 childhood kidney cell carcinoma 10.8
39 cowden syndrome 1 10.8
40 tumor predisposition syndrome 10.8
41 cowden syndrome 3 10.8
42 cowden syndrome 2 10.8
43 cowden syndrome 5 10.8
44 cowden syndrome 6 10.8
45 tuberous sclerosis-1 10.8
46 cowden syndrome 7 10.8
47 cowden syndrome 4 10.8
48 angelman syndrome due to a point mutation 10.8 CA9 HNF1A PBRM1 TFE3 VHL
49 non-distal trisomy 10q 10.7 DIRC3 FHIT MET VEGFA
50 diffuse lipomatosis 10.6 VEGFA VHL

Graphical network of the top 20 diseases related to Renal Cell Carcinoma:



Diseases related to Renal Cell Carcinoma

Symptoms & Phenotypes for Renal Cell Carcinoma

Clinical features from OMIM:

144700

Human phenotypes related to Renal Cell Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 32 HP:0005584

UMLS symptoms related to Renal Cell Carcinoma:


flank pain

MGI Mouse Phenotypes related to Renal Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.15 VEGFA VHL AKT1 ATM CA9 FHIT
2 homeostasis/metabolism MP:0005376 10.1 AKT1 ATM FHIT FLCN HNF1A HNF1B
3 embryo MP:0005380 10.09 VEGFA VHL AKT1 ATM FLCN HNF1B
4 immune system MP:0005387 10.07 AKT1 ATM CA9 FHIT FLCN HNF1B
5 endocrine/exocrine gland MP:0005379 10.06 AKT1 ATM CA9 HNF1A HNF1B IL2
6 digestive/alimentary MP:0005381 10 VHL CA9 FHIT HNF1A IL2 MET
7 mortality/aging MP:0010768 9.83 IL2 MET OGG1 PBRM1 SETD2 TFE3
8 liver/biliary system MP:0005370 9.81 AKT1 HNF1A HNF1B IL2 MET OGG1
9 neoplasm MP:0002006 9.28 AKT1 ATM FHIT FLCN IL2 MET

Drugs & Therapeutics for Renal Cell Carcinoma

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis March 2009
2
Avastin 17 46 BEVACIZUMAB Genentech July 2009
3
Inlyta 17 46 AXITINIB Pfizer January 2012
4
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Proleukin 17 46 ALDESLEUKIN Chiron January 1998
6
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006
7
Torisel 17 46 TEMSIROLIMUS Wyeth May 2007
8
Votrient 17 46 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
2
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
5
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
6
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
7
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
8 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
9
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
10
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
11
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
12
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
13
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
14
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
15
Zoledronic acid Approved Phase 4,Phase 2,Phase 1 118072-93-8 68740
16
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
18
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
19
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
20
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
21
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
22
Nicotine Approved Phase 4 54-11-5 942 89594
23
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
24
Azathioprine Approved Phase 4 446-86-6 2265
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-67-6 938
27
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 98-92-0 936
28
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
33 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
36 interferons Phase 4,Phase 2,Phase 3,Phase 1
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Nicotinic Acids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1510)

id Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
3 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Completed NCT01339962 Phase 4
4 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma Completed NCT00460798 Phase 4
5 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
6 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
7 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
8 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
9 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
10 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
11 Sorafenib in Elderly mRCC Completed NCT01728948 Phase 4 Sorafenib (Nexavar, BAY43-9006)
12 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
13 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
14 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
15 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
16 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
17 Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors Recruiting NCT02700568 Phase 4 axitinib
18 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4 RAD001
19 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
20 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
21 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
22 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
23 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Active, not recruiting NCT01266837 Phase 4 Everolimus
24 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
25 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
26 Cost Effectiveness Of Sunitinib In Central America And Caribbean Terminated NCT01033981 Phase 4 Sunitinib
27 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
28 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Terminated NCT01073644 Phase 4 Sunitinib malate
29 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
31 A Post Marketing Surveillance As Required By Philippine Food And Drug Administration Withdrawn NCT01781442 Phase 4 Temsirolimus
32 Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Withdrawn NCT01353794 Phase 4 Sorafenib (Nexavar, BAY43-9006)
33 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
34 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
35 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
36 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
37 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
38 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
39 Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) Completed NCT00478114 Phase 3 sorafenib
40 IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Completed NCT01265901 Phase 3 Sunitinib;Cyclophosphamide;IMA901
41 Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96
42 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
43 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
44 ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00420888 Phase 2, Phase 3 ABR-217620/naptumomab estafenatox;IFN-alpha
45 A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib
46 Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Completed NCT01613846 Phase 3 Sorafenib+Pazopanib;Pazopanib+Sorafenib
47 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
48 Sequential Study to Treat Renal Cell Carcinoma Completed NCT00732914 Phase 3 Sunitinib (Sutent);Sorafenib (Nexavar)
49 Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer Completed NCT00003126 Phase 3 Interleukin-2
50 Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis Completed NCT00291369 Phase 3 Interleukin-2;Interferon alfa;medroxyprogesterone acetate

Search NIH Clinical Center for Renal Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma

Genetic tests related to Renal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29
2 Renal Cell Carcinoma 29 24 HNF1A

Anatomical Context for Renal Cell Carcinoma

MalaCards organs/tissues related to Renal Cell Carcinoma:

39
Kidney, Endothelial, Lung, Bone, T Cells, Brain, Prostate

Publications for Renal Cell Carcinoma

Articles related to Renal Cell Carcinoma:

(show top 50) (show all 5369)
id Title Authors Year
1
The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell Carcinoma. ( 28551621 )
2017
2
Renal Cell Carcinoma in a Pregnant Woman With Horseshoe Kidney. ( 28507908 )
2017
3
The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma. ( 28459210 )
2017
4
Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far From the Tree. ( 28912138 )
2017
5
Analysis of long non-coding RNA expression profiles in clear cell renal cell carcinoma. ( 28928816 )
2017
6
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. ( 28532444 )
2017
7
Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma. ( 27993630 )
2017
8
Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. ( 27864122 )
2017
9
Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level. ( 27866460 )
2017
10
Image-guided ablation of renal cell carcinoma. ( 28527529 )
2017
11
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. ( 28061437 )
2017
12
A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. ( 28512261 )
2017
13
Association of membranoproliferative glomerulonephritis with renal cell carcinoma. ( 28004485 )
2017
14
KLF6 Suppresses Metastasis of Clear Cell Renal Cell Carcinoma via Transcriptional Repression of E2F1. ( 27780824 )
2017
15
An association between overexpression of DNA methyltransferase 3B4 and clear cell renal cell carcinoma. ( 28160561 )
2017
16
Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. ( 28257806 )
2017
17
High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. ( 28938681 )
2017
18
A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. ( 28938589 )
2017
19
Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma. ( 28391274 )
2017
20
Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3I^/I^-catenin signaling pathway. ( 28846080 )
2017
21
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. ( 28614790 )
2017
22
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. ( 28300276 )
2017
23
G Protein Alpha S Subunit Promotes Cell Proliferation of Renal Cell Carcinoma with Involvement of Protein Kinase A Signaling. ( 28051330 )
2017
24
High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma. ( 28393205 )
2017
25
MiR-99A Suppresses Proliferation, Migration, Invasion and Induces G1-Phase Cell Cycle Arrest via Targeting IGF-1R Pathway in Renal Cell Carcinoma 786-0 and OS-RC-2 Cells. ( 28088554 )
2017
26
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. ( 28522811 )
2017
27
Downregulation of OCLN and GAS1 in clear cell renal cell carcinoma. ( 28184927 )
2017
28
Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma. ( 28928896 )
2017
29
Prognostic Value of Inflammatory and Nutritional Scores in Renal Cell Carcinoma After Nephrectomy. ( 28528087 )
2017
30
Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). ( 28736828 )
2017
31
Small (< 4 cm) Renal Tumors With Predominantly Low Signal Intensity on T2-Weighted Images: Differentiation of Minimal-Fat Angiomyolipoma From Renal Cell Carcinoma. ( 27824487 )
2017
32
Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis? ( 28009604 )
2017
33
Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer. ( 27983522 )
2017
34
The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review. ( 28725540 )
2017
35
Long non-coding RNA CCAT2 promotes cell proliferation and invasion through regulating Wnt/I^-catenin signaling pathway in clear cell renal cell carcinoma. ( 28718366 )
2017
36
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. ( 28154184 )
2017
37
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. ( 28089886 )
2017
38
Time to Focus on the Rare-Encouraging Progress in the Management of Non-clear Cell Renal Cell Carcinoma. ( 28822585 )
2017
39
LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495. ( 28466784 )
2017
40
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. ( 28531203 )
2017
41
Periostin promotes migration and invasion of renal cell carcinoma through the integrin/focal adhesion kinase/c-Jun N-terminal kinase pathway. ( 28381189 )
2017
42
Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. ( 28523353 )
2017
43
Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. ( 27638770 )
2017
44
Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. ( 28639901 )
2017
45
Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape. ( 28710314 )
2017
46
High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. ( 28533485 )
2017
47
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. ( 27841868 )
2017
48
Tim-3 Expression on Tumor-Infiltrating PD-1(+)CD8(+) T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. ( 27872087 )
2017
49
Metastatic sarcomatoid renal cell carcinoma manifesting as a subcutaneous soft tissue mass. ( 28675457 )
2017
50
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma. ( 28050950 )
2017

Variations for Renal Cell Carcinoma

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma:

71
id Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

ClinVar genetic disease variations for Renal Cell Carcinoma:

6 (show all 37)
id Gene Variation Type Significance SNP ID Assembly Location
1 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 GRCh37 Chromosome 3, 10191555: 10191555
2 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic/Likely pathogenic rs5030818 GRCh37 Chromosome 3, 10191488: 10191488
3 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic/Likely pathogenic rs5030820 GRCh37 Chromosome 3, 10191506: 10191506
4 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
5 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
6 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
9 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
10 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
11 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
12 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
13 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
14 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
15 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
16 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
17 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
18 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
19 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
20 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
21 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
22 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
23 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
24 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
25 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
26 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
27 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
28 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387
29 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
30 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
32 MTOR NM_004958.3(MTOR): c.4447T> C (p.Cys1483Arg) single nucleotide variant Pathogenic/Likely pathogenic rs1057519914 GRCh38 Chromosome 1, 11157174: 11157174
33 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
34 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
35 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
36 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh37 Chromosome 1, 11184573: 11184573
37 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905

Cosmic variations for Renal Cell Carcinoma:

9 (show top 50) (show all 1325)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 46
2 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 46
3 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 46
4 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 46
5 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 46
6 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 46
7 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 46
8 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 46
9 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 46
10 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 46
11 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 46
12 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 46
13 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 30
14 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 30
15 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 30
16 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 30
17 COSM5012058 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 30
18 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 30
19 COSM5010682 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 30
20 COSM5013462 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 30
21 COSM5011020 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3322G>T p.D1108Y 30
22 COSM5014655 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 30
23 COSM5012645 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1218C>A p.F406L 30
24 COSM2888871 XKR7 kidney,NS,carcinoma,papillary renal cell carcinoma c.1409C>T p.T470M 30
25 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 30
26 COSM6201648 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1228+1G>C p.? 30
27 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 30
28 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 30
29 COSM30715 WISP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.868T>C p.C290R 30
30 COSM5012777 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 30
31 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 30
32 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 30
33 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 30
34 COSM17855 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.233A>G p.N78S 30
35 COSM17807 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.264G>C p.W88C 30
36 COSM30224 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.326T>G p.I109S 30
37 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 30
38 COSM17715 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.221T>A p.V74D 30
39 COSM14309 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.478G>A p.E160K 30
40 COSM14408 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.485G>A p.C162Y 30
41 COSM17612 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.481C>T p.R161* 30
42 COSM1169455 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>G p.Y175* 30
43 COSM17928 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463G>C p.V155L 30
44 COSM17948 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.172C>A p.R58R 30
45 COSM18379 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.505C>T p.L169L 30
46 COSM3734681 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.511A>T p.K171* 30
47 COSM17658 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 30
48 COSM17934 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.452T>C p.I151T 30
49 COSM17651 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.445G>C p.A149P 30
50 COSM34019 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.361G>T p.D121Y 30

Copy number variations for Renal Cell Carcinoma from CNVD:

7 (show top 50) (show all 1298)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma patients vs. healthy controls: 35 (show top 50) (show all 278)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SLC12A1 solute carrier family 12 (sodium/potassium/chloride transporter), member 1 Kidney - 9.35 0.000
2 CALB1 calbindin 1, 28kDa Kidney - 8.95 0.000
3 FXYD4 FXYD domain containing ion transport regulator 4 Kidney - 8.29 0.000
4 CLDN8 claudin 8 Kidney - 8.20 0.000
5 KCNJ1 potassium channel, inwardly rectifying subfamily J, member 1 Kidney - 8.20 0.000
6 NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) Kidney - 8.18 0.000
7 MUC15 mucin 15, cell surface associated Kidney - 7.96 0.000
8 SCNN1G sodium channel, non voltage gated 1 gamma subunit Kidney - 7.91 0.000
9 HPD 4-hydroxyphenylpyruvate dioxygenase Kidney - 7.78 0.000
10 FABP1 fatty acid binding protein 1, liver Kidney - 7.74 0.000
11 DNASE1 deoxyribonuclease I Kidney - 7.59 0.000
12 SLC7A13 solute carrier family 7 (anionic amino acid transporter), member 13 Kidney - 7.29 0.000
13 ANGPTL4 angiopoietin-like 4 Kidney + 7.25 0.000
14 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 Kidney + 7.16 0.000
15 ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 Kidney - 7.13 0.000
16 PCP4 Purkinje cell protein 4 Kidney - 7.13 0.000
17 KNG1 kininogen 1 Kidney - 7.12 0.000
18 TYRP1 tyrosinase-related protein 1 Kidney - 7.10 0.000
19 FGF9 fibroblast growth factor 9 Kidney - 6.99 0.000
20 EGF epidermal growth factor Kidney - 6.92 0.000
21 RALYL RALY RNA binding protein-like Kidney - 6.81 0.000
22 PVALB parvalbumin Kidney - 6.73 0.000
23 KCNJ10 potassium channel, inwardly rectifying subfamily J, member 10 Kidney - 6.69 0.000
24 TMEM213 transmembrane protein 213 Kidney - 6.64 0.000
25 SLC22A8 solute carrier family 22 (organic anion transporter), member 8 Kidney - 6.58 0.000
26 IRX2 iroquois homeobox 2 Kidney - 6.56 0.000
27 SLC26A7 solute carrier family 26 (anion exchanger), member 7 Kidney - 6.56 0.000
28 SLC4A1 solute carrier family 4 (anion exchanger), member 1 (Diego blood group) Kidney - 6.53 0.000
29 GPC5 glypican 5 Kidney - 6.53 0.000
30 RHCG Rh family, C glycoprotein Kidney - 6.52 0.000
31 SOST sclerostin Kidney - 6.51 0.000
32 SFRP1 secreted frizzled-related protein 1 Kidney - 6.49 0.000
33 HEPACAM2 HEPACAM family member 2 Kidney - 6.45 0.000
34 NELL1 neural EGFL like 1 Kidney - 6.38 0.000
35 SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 Kidney - 6.34 0.000
36 RAB25 RAB25, member RAS oncogene family Kidney - 6.32 0.000
37 TMPRSS2 transmembrane protease, serine 2 Kidney - 6.31 0.000
38 TMEM52B transmembrane protein 52B Kidney - 6.28 0.000
39 ERBB4 erb-b2 receptor tyrosine kinase 4 Kidney - 6.26 0.000
40 SOSTDC1 sclerostin domain containing 1 Kidney - 6.25 0.000
41 SH3GL2 SH3-domain GRB2-like 2 Kidney - 6.16 0.000
42 ALDOB aldolase B, fructose-bisphosphate Kidney - 6.13 0.003
43 APOC1 apolipoprotein C-I Kidney + 6.11 0.000
44 UMOD uromodulin Kidney - 6.07 0.000
45 NPTX2 neuronal pentraxin II Kidney + 6.05 0.000
46 LOC284578 uncharacterized LOC284578 Kidney - 6.02 0.000
47 ESRRB estrogen-related receptor beta Kidney - 5.99 0.000
48 SLC13A3 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 Kidney - 5.96 0.001
49 TSPAN8 tetraspanin 8 Kidney - 5.96 0.000
50 WNK4 WNK lysine deficient protein kinase 4 Kidney - 5.94 0.000
Search GEO for disease gene expression data for Renal Cell Carcinoma.

Pathways for Renal Cell Carcinoma

Pathways related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.49 AKT1 FLCN MET VEGFA VHL
2
Show member pathways
12.18 AKT1 ATM IL2 MET
3 11.71 ATM MET PRCC TFE3
4
Show member pathways
11.69 AKT1 HNF1A HNF1B
5 11.67 AKT1 VEGFA VHL
6
Show member pathways
11.64 AKT1 HNF1A HNF1B
7
Show member pathways
11.57 AKT1 VEGFA VHL
8 11.36 AKT1 ATM SETD2
9 11.32 AKT1 ATM IL2
10 11.25 AKT1 CA9 VEGFA
11 10.9 AKT1 CA9 VEGFA
12 10.75 VEGFA VHL
13 10.51 AKT1 HNF1A VEGFA

GO Terms for Renal Cell Carcinoma

Biological processes related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.73 AKT1 HNF1B IL2 OGG1 VEGFA VHL
2 positive regulation of protein phosphorylation GO:0001934 9.67 AKT1 FLCN IL2 VEGFA
3 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.61 CA9 VEGFA VHL
4 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.56 AKT1 FLCN HNF1A HNF1B IL2 MET
5 positive regulation of cell adhesion GO:0045785 9.5 FLCN TFE3 VEGFA
6 TOR signaling GO:0031929 9.46 AKT1 FLCN
7 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 9.4 HNF1A HNF1B
8 branching morphogenesis of an epithelial tube GO:0048754 9.33 HNF1B MET VEGFA
9 regulation of pronephros size GO:0035565 8.62 HNF1A HNF1B

Sources for Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....